SSi Canada Partners with SES Networks to Deliver New Satellite Capacity into Northern Canada
18.1.2021 19:40:00 EET | Business Wire | Press release
Vital new satellite capacity will be delivered to Canada’s north, including all 25 communities of Nunavut, following a partnership signed between SSi Canada, the developer-operator of QINIQ broadband and SSi Mobile services in Nunavut, and SES Networks, the leader in global content connectivity solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210118005410/en/
SSi Canada Partners with SES Networks to Deliver New Satellite Capacity into Northern Canada (Photo: Business Wire)
This partnership comes at a critical time for Nunavut, with the COVID-19 crisis having led to an unprecedented need for reliable internet and mobile communications services as Nunavummiut move increasingly to study, work, and shop online and at home. With growing demand for QINIQ broadband and SSi Mobile services, all 25 communities in Nunavut - and elsewhere in Northern Canada - will benefit from SSi Canada’s multi-year agreement with SES Networks.
“We are excited to partner with SES Networks to bring this much needed capacity to Canada’s North,” said Jeff Philipp, CEO and Founder of SSi. “As a global operator, SES Networks understands the challenges faced by underserved regions of the world and SSi’s ongoing commitment to overcome these challenges. SES Networks is certainly the right partner at the right time.”
Under the new agreement announced today, SSi Canada will secure a significant increase in its satellite capacity, enhancing SSi’s ability to better serve consumers, students, government entities and businesses in Nunavut today and into the future. The new SES-SSi satellite footprint covers much more than Nunavut, enabling connectivity improvements across Canada.
“Thanks to timely regulatory approvals from the Canadian Government, we are now working hard to bring this new capacity online as quickly as possible” said Philipp. “This is an essential step to ensure continuity of QINIQ broadband, and we look forward to expanding our network offerings and capabilities in the coming months and years as we work to deliver on the Government’s goal of broadband connectivity for every Canadian, no matter where they live.”
“For years we’ve been providing services to Northern Canada and know that the digital divide is challenging for people living in remote and rural areas,” said Omar Trujillo, Vice President of Sales, Fixed Data Americas at SES Networks. “Canada’s bold vision to connect every citizen to broadband this decade aligns with the innovative solutions SSi Canada has been providing to its customers for years. We are happy to bring our expertise of operating more than 70 geostationary and medium earth orbit satellites to help SSi Canada scale up their backbone, ensuring that the remote communities in Nunavut are at the forefront in achieving the 50/10 Mbps threshold.”
SES has a proven track record for providing reliable data services across Canada in a variety of spectrum bands over its satellite fleet. Its C-band offerings are uniquely capable for providing the capacity needed for communities and businesses in Canada to maintain and strengthen their communications infrastructure.
Follow SES on:
Social Media
Blog
Media Library
About SSi Canada
Headquartered in Yellowknife, Northwest Territories, with a satellite teleport and network operations centre in Ottawa, SSi designs, builds and operates state-of-the-art communications networks. SSi is a pioneer in delivering remote-area connectivity in Canada’s North and the developer-operator of the award winning SSi Mobile and QINIQ broadband services. With over 30 years of operating experience, SSi is a leader in delivering advanced satellite, broadband, mobile wireless and clean energy solutions. SSi understands first-hand the challenges faced in providing effective and affordable communications services and other infrastructure support to remote and outlying areas, having launched broadband and mobile voice and data services into many markets where these previously did not exist.
For more information, see: http://www.ssicanada.com/
About SES
SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries almost 8,200 channels and has an unparalleled reach of 367 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG).
Further information is available at: www.ses.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210118005410/en/
Contact information
Suzanne Ong
SES External Communications
Tel. +352 710 725 500
suzanne.ong@ses.com
David Veniot
SSi Communications Manager
Tel. 613-271-6464
davidv@ssicanada.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
